LRRK2

John M Hatcher1, Monika Zwirek2, Adil R Sarhan3

  • 1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, 360 Longwood Ave, Longwood Center LC-2209, Boston, MA 02115, USA.

概括

研究人员开发了一种新型的PROTAC分子,以准帕金森病 (PD) 中的氨酸丰富的重复激酶2 (LRRK2). 这种分子有效地降低了LRRK2激酶活性和支架功能,为PD提供了潜在的新治疗策略.